Journal of Diabetes Investigation · 2015 · 32 citations · 16 references
MedicineEndocrinologyPharmacologyClinical NutritionClinical PharmacologyPharmacovigilanceDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyObesity ManagementSodium-glucose Cotransporter 2 InhibitorsWeight ManagementClinical Trial Efficacy EndpointsHemoglobin A1c TestingObesity TreatmentPlacebo ComparatorsRandomized Clinical TrialsRandomized Crossover TrialsSafety Subgroup AnalysisSodium-glucose Cotransporter 2 Inhibition
AIMS/INTRODUCTION: The influence of overweight/obesity on the clinical efficacy and safety of sodium-glucose co-transporter 2 inhibitors is unclear. We carried out a pooled analysis to examine the impact of body mass index on the efficacy and safety of ipragliflozin. MATERIALS AND METHODS: Patient-level data were pooled for five Japanese double-blind trials (NCT00621868, NCT01057628, NCT01135433, NCT01225081 and NCT01242215) in which patients were randomized to ipragliflozin or a placebo as monotherapy, or in combination with metformin, pioglitazone or a sulfonylurea. Outcomes included the changes in hemoglobin A1c, fasting plasma glucose, bodyweight and treatment-emergent adverse events. Patients were divided into four body mass index categories. RESULTS: Hemoglobin A1c, fasting plasma glucose and bodyweight decreased significantly in the ipragliflozin group compared with the placebo group in all body mass index categories, and in the total cohort (all P < 0.001). Hemoglobin A1c did not improve in 11.2 and 69.2% of patients in the ipragliflozin and placebo groups, respectively. The change in hemoglobin A1c was weakly correlated with the change in bodyweight in all patients (r = 0.136, P = 0.002). Regarding laboratory variables, the placebo-subtracted difference tended to be greater in patients with higher body mass index for aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase and uric acid. The incidences of treatment-emergent adverse events were similar between the ipragliflozin and placebo groups in all patients combined and in the four body mass index categories. CONCLUSIONS: These results show that the efficacy and safety of ipragliflozin are not influenced by obesity/overweight in Japanese patients.
16
Atsunori Kashiwagi, Masato Kasuga, Eiichi Araki et al. · Journal of Diabetes Investigation · 2012 · 897 citations · Full text
Jan Bolinder, Östen Ljunggren, Joel Kullberg et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 860 citations
Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology · 2014 · 194 citations · Full text
Paul Nyirjesy, Yue Zhao, Kirk Ways et al. · Current Medical Research and Opinion · 2012 · 148 citations